ADC

Eli Lilly to Acquire CrossBridge Bio for ADC Platform

Houston, Texas, U.S. | April 15, 2026 Eli Lilly and Company has announced a strategic agreement to acquire CrossBridge...

By cGxPwire Editor
April 16, 2026

Bio-Pharma

AbbVie Reports Strong Phase 2 Data in Ovarian Cancer

North Chicago, Illinois | April 12, 2026 AbbVie has announced late-breaking Phase 2 clinical trial results demonstrating strong efficacy...

By cGxPwire Editor
April 13, 2026

Bio-Pharma

Tempus, Daiichi Sankyo Advance AI in ADC Oncology Trials

CHICAGO, Illinois, March 25, 2026 Tempus AI has announced a strategic collaboration with Daiichi Sankyo to accelerate AI-driven biomarker...

By cGxPwire Editor
March 26, 2026

Pharma

FDA Clears New KEYTRUDA Regimens for Bladder Cancer Care

Rahway, N.J., Nov. 21, 2025 — In a major advancement for oncology treatment, the U.S. Food and Drug Administration...

By cGxPwire Editor
November 24, 2025

M&A

Day One Biopharma Acquires Mersana to Advance ADC Pipeline

BRISBANE, CA – November 13, 2025 — Day One Biopharmaceuticals announced a definitive agreement to acquire Mersana Therapeutics in...

By cGxPwire Editor
November 13, 2025

Find Jobs Across Pharma, Biotech & Life Sciences

Discover verified job opportunities from top companies worldwide. Apply easily and grow your career in the life sciences industry.

Bio-Pharma

Whitehawk Therapeutics Identifies PTK7 as a Broadly Expressed ADC Target Across Solid Tumors

MORRISTOWN, N.J. | October 24, 2025 — Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology-focused biopharmaceutical company pioneering next-generation antibody-drug...

By cGxPwire Editor
October 24, 2025

.Clinical Bio-Pharma

Adcendo Secures FDA Fast Track for ADCE-D01 Targeting Soft Tissue Sarcoma

COPENHAGEN, Denmark, Oct. 9, 2025 – (cGxP.wire) – Adcendo ApS, a biotechnology company pioneering first- and best-in-class antibody-drug conjugates...